Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01694485 · ClinicalTrials.gov registry record · Phase 2
Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 359
- Enrollment target
NCT01694485 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 359 participants.
The verdict
NCT01694485, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 359 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the effect of abrilumab on induction of remission in adults with moderate to severe ulcerative colitis after 8 weeks of treatment as assessed by a total Mayo Score ≤ 2 points, with no individual subscore \> 1 point.
Interventions
- DRUG Placebo
- BIOLOGICAL Abrilumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 359 participants |
| Start Date | 2012-11-16 |
| Est. Completion | 2018-04-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01694485
The ClinicalTrials.gov registry entry for NCT01694485 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 359 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01694485 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01694485 about?
NCT01694485 is a clinical study titled "Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis". The primary objective of this study is to evaluate the effect of abrilumab on induction of remission in adults with moderate to severe ulcerative colitis after 8 weeks of treatment as assessed by a total Mayo Score ≤ 2 points, with no individual subscore \> 1 point.
What is the current status of trial NCT01694485?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 359 participants. The study started on 2012-11-16. Estimated completion is 2018-04-10.
What interventions are being tested in trial NCT01694485?
The interventions under investigation include: Placebo (DRUG), Abrilumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01694485?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.